ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Threshold Pharmaceuticals, Inc." (THLD) Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Threshold Pharmaceuticals, Inc." (THLD)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: ANAC, LGND, EVGN, BSTC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: D down no change
Last Week: D same downgrade
Two Weeks Ago: C up no change
service keys

"Threshold Pharmaceuticals, Inc."© quotemedia

Company Profile

Threshold Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of drugs for the microenvironment of solid tumors and the bone marrows of hematologic malignancies as novel treatments for patients living with cancer. Its clinical development products include TH-302, a novel drug candidate, which is in Phase I, Phase II, and Phase III clinical trials for the severe hypoxic regions present in various solid tumors and hematologic malignancies. The company has a license and co-development agreement with Merck KGaA for the development and commercialization of TH-302; and license agreement with Eleison Pharmaceuticals, Inc. to develop and commercialize glufosfamide for the treatment of cancer in humans and animals. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

Recent News: "Threshold Pharmaceuticals, Inc."